2025-05-08-Jefferies-赛普特（CYRX）_季度表现良好_重申收入指引；现金状况带来诸多灵活性_9页_208kb

Cryoport Inc. (CYRX) is a leading global provider of critical cold chain logistics solutions for temperature-sensitive materials in the life sciences sector, with operations in Biopharma, Animal Health, and Reproductive Health. Founded in 1990 and headquartered in Brentwood, TN, the company has shown strong recent performance, including a 2% revenue beat in Q1 2025 due to growth in services, particularly in Biologics and Bioservices. Financial metrics indicate improving gross margins (up 500bps year-on-year) and adjusted EBITDA targets to reach positive levels in 2025, with 2025 revenue guidance at $165-172M (+5-10% year-over-year), supported by CGT approvals and commercial activity. The valuation offers a price target of $6.50, implying an EV/revs ratio of about 1.7x for 2025, which aligns with a HOLD rating due to risks like CGT funding uncertainties, competition from larger peers, clinical trial outcomes, and potential impacts from China tariffs. Long-term upside is tied to cell and gene therapy markets, but execution and market dynamics uncertainty could limit growth. Key catalysts include new CGT approvals, M&A activity, and adoption of innovative products. Analyst disclosures confirm potential conflicts of interest, and historical ratings reflect volatility, with a current emphasis on mid-term stability amid macroeconomic challenges.